Last reviewed · How we verify
ISOSULFAN BLUE INNER SALT
Isosulfan Blue Inner Salt is a marketed drug with a key composition patent expiring in 2028. The drug's market position and specific mechanism of action are not detailed, but its patent protection provides a competitive advantage until expiry. The primary risk is the potential for increased competition post-2028, which could impact revenue.
At a glance
| Generic name | ISOSULFAN BLUE INNER SALT |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISOSULFAN BLUE INNER SALT CI brief — competitive landscape report
- ISOSULFAN BLUE INNER SALT updates RSS · CI watch RSS